Inotiv receives waiver of minimum liquidity covenant for March test dates

Key numbers: Q1 2026 EPS -$0.83 vs -$0.51 expected (62.75% negative surprise); revenue $120.9M vs $126.53M expected. Lenders granted a limited waiver of the minimum liquidity covenant for the March 20 and March 27, 2026 test dates under the company's Nov 5, 2021 Credit Agreement, with no other amendments. The company also disclosed a cybersecurity breach detected Aug 8, 2025 that may have exposed SSNs and financial account data for current/former employees and family members, all of which heighten downside risk to investor sentiment and share performance.

Analysis

Lender willingness to provide narrowly scoped covenant relief typically signals an acute-but-manageable liquidity stress rather than an immediate insolvency; the second-order effect is operational conservatism (cash sweeps, hiring freezes, paused capex) that compresses near-term growth and makes the company vulnerable to loss of discretionary customer projects. Expect lenders to push for pre-emptive equity or asset-sale solutions inside a 1–3 month window — failure to secure those will materially widen credit spreads and force an accelerated deleveraging that can shave 20–40% off equity value quickly.

A data-privacy incident shifts the competitive game from pure service excellence to trust and compliance differentiation; buyers of regulated lab/CRO services reallocate work slowly but decisively, creating a 3–12 month window where better-capitalized peers can selectively increase market share without price wars. Remediation plus potential regulator/class-action exposure is often front-loaded (legal/remediation costs in month 0–6) but revenue leakage is the multi-year damage driver and is best modelled as a 2–6% recurring top-line haircut per lost mid-sized client.

Catalysts to watch that will reprice both equity and credit: lender covenant renewals/re-negotiations, announced bridge/equity financing, confirmed client migrations or wins, and any regulatory enforcement letters. The share is binary over a 3–9 month horizon — either a credible financing/capacity plan is delivered and the stock rerates, or the market reprices for restructuring and higher recovery spreads. Positioning should therefore be event-driven and size-constrained with explicit stop/roll rules.

Key Decisions for Investors

• Short equity bias: Buy 3–6 month puts on NOTV (25–35% OTM) sized to 1.5–2% of fund NAV; target 35–55% downside if financing fails, stop at 25% premium loss. Timeframe: 1–3 months to the next covenant/capital event.
• Pair trade (risk-reducing): Short NOTV equity vs long CRL (Charles River Laboratories, CRL) 1.5:1 by notional for a 3–12 month trade — expected to capture 200–400bps relative alpha if customers reallocate to larger, better-capitalized CROs.
• Credit/structured idea: For credit desks, buy protection via CDS or short unsecured NOTV bonds if spreads exceed 600bps over curves; target 3:1 payoff-to-premium in a distressed-restructuring scenario within 6–18 months.
• Event-driven contrarian: Take a small (0.5–1% NAV) long-call position (OTM, 6–9 month tenor) conditional on a confirmed asset-sale or committed bridge financing announcement — asymmetric upside if management delivers a clean liability fix.